Author

A. Clear

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Organism:mouse· 1

Frequent Co-Authors

J. Gribben· 3 shared A. D'Avola· 2 shared J. Fitzgibbon· 2 shared J. Wang· 2 shared M. Calaminici· 2 shared P. Chakravarty· 2 shared A. F. Al Seraihi· 1 shared A. Gunawan· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 34 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. Gribben

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

PHGDH is required for germinal center formation and is a therapeutic target in MYC-driven lymphoma

A. D'Avola, N. Legrave, M. Tajan, P. Chakravarty, R. Shearer, H. King, E. Cheung, A. Clear, A. Gunawan, L. Zhang, L. James, J. MacRae, J. Gribben, D. Calado, K. Vousden, J. Riches

This study identifies PHGDH as essential for germinal center formation and shows its inhibition reduces lymphoma progression and improves survival.

bioRxiv · Nov 11, 2021Immunology

KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas

J. A. Heward, L. Koniali, A. D'Avola, K. Close, A. Yeomans, M. Philpott, J. Dunford, T. Rahim, A. F. Al Seraihi, J. Wang, K. Korfi, S. Araf, S. Iqbal, F. Bewicke-Copley, E. Kumar, , J. Fitzgibbon

This study shows that inhibiting KDM5 demethylases restores H3K4 methylation and reactivates genes in KMT2D mutant lymphomas, offering a potential therapeutic strategy.

bioRxiv · Jun 30, 2020Cancer Biology

Co-activation of NF-κB and MYC renders cancer cells addicted to IL6 for survival and phenotypic stability

R. Barbosa, A. Q. Xu, D. D'Andrea, F. Copley, H. Patel, P. Chakravarty, A. Clear, M. Calaminici, M. Janz, B. Zhang, M. Schmidt-Supprian, J. Wang, J. Gribben, R. Tooze, J. Fitzgibbon, , D. P. Calado

This paper shows that co-activation of NF-κB and MYC in cancer cells makes them dependent on IL6 for survival and leads to a poorly-differentiated state similar to human plasmablastic lymphoma and t(8;14)[MYC-IGH] multiple myeloma.

bioRxiv · Apr 12, 2020 · PreprintCancer Biology